ALLO Allogene Therapeutics, Inc.
$0.67
Allogene Therapeutics, Inc. (ALLO) Earnings News
Earnings press releases, previews and reviews for Allogene Therapeutics, Inc. (ALLO), newest first. Our most recent is review: Allogene Misses on a Wider Loss as ALPHA3 Enrollment Accelerates but Interim-Data Expectations Cool.
Thursday
November 5, 2026
9:12 PM ET
Allogene Misses on a Wider Loss as ALPHA3 Enrollment Accelerates but Interim-Data Expectations Cool
Earnings Whispers · Review
Thursday
November 5, 2026
4:02 PM ET
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Thursday
October 29, 2026
12:02 PM ET
Allogene's 39% Slide Puts Cash Runway and Alpha-3 Execution Under the Microscope
Earnings Whispers · Preview
Thursday
October 29, 2026
8:30 AM ET
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Wednesday
August 12, 2026
4:05 PM ET
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
Tuesday
August 4, 2026
8:30 AM ET
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update